Key result
Warfarin is more effective than aspirin for preventing stroke in non-rheumatic atrial fibrillation, reducing the absolute risk of ischaemic stroke and systemic embolism by 1.2% in patients over 75 years.
Why the study?
There is controversy and apprehension regarding the routine use of oral anticoagulants in atrial fibrillation, especially in elderly people.
Does prophylactic anticoagulant therapy prevent embolic stroke in older people with non-rheumatic atrial fibrillation?
Does prophylactic anticoagulant therapy prevent embolic stroke in older people with non-rheumatic atrial fibrillation?
Prophylactic anticoagulation with warfarin (or aspirin if intolerant) is recommended for stroke prevention in older patients with non-rheumatic atrial fibrillation, rather than waiting for a transient ischemic attack or stroke to occur.
Answers are grounded in this paper and cite their sources.
Supports anticoagulation for stroke prevention in eligible non-rheumatic AF; leaves open optimal strategies for elderly patients with contemporary agents.
There is controversy and apprehension regarding the routine use of oral anticoagulants in atrial fibrillation, especially in elderly people. Based on current evidence, however, patients with non-rheumatic atrial fibrillation who have no obvious contraindications to warfarin should receive prophylactic anticoagulant therapy for prevention of embolic stroke. Patients unable to tolerate warfarin would benefit from aspirin. It is poor clinical practice to await transient ischaemic attacks or a stroke before considering anticoagulation, and it should be remembered that cost–benefit values need to include the cost of rehabilitation and long-term care.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (1999) conducted an editorial in Non-rheumatic atrial fibrillation. Warfarin vs. Aspirin or placebo was evaluated on Ischaemic stroke and systemic embolism (ARR 1.2%). Warfarin is more effective than aspirin for preventing stroke in non-rheumatic atrial fibrillation, reducing the absolute risk of ischaemic stroke and systemic embolism by 1.2% in patients over 75 years.
Synapse has enriched 10 related papers. Consider them for comparative context: